Promising Early Results for Potent, Long-Acting HIV Injection

A highly potent, long-acting drug candidate with a novel mode of action showed promising anti-HIV activity in recent phase 1 trials. The slow-release compound, lenacapavir (previously GS-6207), would be used in combination with other antiretroviral agents, researchers said at the 23rd International AIDS Conference.
Source: JAMA - Category: General Medicine Source Type: research